Juq-063 -

Ready to explore how JUQ-063 can empower your region? Connect with NovaTech to learn about pilot programs and partnerships. Let’s build a sustainable future—together.

If "JUQ-063" is a code for a specific type of paper, here are some general steps involved in producing paper: JUQ-063

The film is structured in three main acts: Ready to explore how JUQ-063 can empower your region

| Indication | Current therapies | Limitations | |------------|-------------------|-------------| | | SSRIs, SNRIs, atypicals, ketamine/esketamine | Delayed onset, residual anhedonia, high relapse. | | Alcohol‑Use Disorder (AUD) | Naltrexone, acamprosate, disulfiram | Modest efficacy, poor adherence, limited effect on stress‑induced drinking. | | Stress‑Related Anxiety / PTSD | SSRIs, SNRIs, benzodiazepines | Sedation, dependence, limited efficacy on hyper‑arousal. | ketamine/esketamine | Delayed onset